Get the Stockscreener App
5.7615
0.52%
-0.0185
Alpha Cognition Inc stock is traded at $5.7615, with a volume of 15,684.
It is down -0.52% in the last 24 hours and up +0.00% over the past month.
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
See More
Previous Close:
$5.78
Open:
$5.85
24h Volume:
15,684
Relative Volume:
1.97
Market Cap:
$36.50M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-7.41M
1W Performance:
+1.32%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.75
$5.85
1-Week Range:
$5.35
$5.85
52-Week Range:
$5.35
$5.85
Alpha Cognition Inc Stock (ACOG) Company Profile
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ACOG | 5.75 | 36.50M | 0 | -14.72M | -7.41M | 0.00 |
| VRTX | 448.26 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.57 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.72 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.24 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Alpha Cognition Inc Stock (ACOG) Latest News
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - Business Wire
Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com
Alpha cognition director John Havens buys $24,995 in common shares - Investing.com India
Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alpha Cognition Inc (ACOGF) Quarterly 10-Q Report - Quartzy
Canada market stock losers: Tidewater Renewables Ltd. looses 12.43% while Rektron Group Inc dips by 10.33% during mid day trading - Business Upturn
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing - Business Wire
Canada Market Top Losers: AYR Wellness down 47.30%, Trulieve Cannabis falls 40%, - Business Upturn
Alpha Cognition Inc. announced that it has received $4.545 million in funding - Marketscreener.com
Alpha Cognition Plans Nasdaq Listing and $25M Offering - TipRanks
Xavier Creative House Hires Jami Rogers as Vice President of Sales & Marketing - citybiz
Alpha Cognition Announces Appointment of VP Finance and Accounting - Business Wire
Alpha Cognition Inc (ACOGF) QuotePress Release - The Globe and Mail
Alpha Cognition Announces Executive Shake-up & Drug Approval - TipRanks
Alpha Cognition Announces Change of Officer - Business Wire
Spartan Capital Securities Serves as Selling Group Member - GlobeNewswire
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing - BioSpace
Alpha Cognition sets annual meeting for September 27 - Investing.com
July FDA approvals target Alzheimer's, myeloma and wet AMD - BioWorld Online
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease - Yahoo Finance
Alpha Cognition Inc. Adjusts Funding Strategy Amid Market Challenges - TipRanks
FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatment - News-Medical.Net
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease - Seeking Alpha
FDA favors Zunveyl, Alzheimer's therapy showing better tolerability - Alzheimer's News Today
FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's disease | 2024-07-29 | Investing News - Stockhouse Publishing
Breakeven On The Horizon For Alpha Cognition Inc. (CSE:ACOG) - Simply Wall St
Alpha Cognition upgraded at Raymond James - Cantech Letter
Early Inflammation Linked to Midlife Cognitive Decline - Neuroscience News
What’s Coming Down the Pike: Drug Approvals in the Second Half of ’24 - Managed Healthcare Executive
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update - Business Wire
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer’s (NASDAQ:CGTX) - Seeking Alpha
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - Yahoo Finance
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now - GlobeNewswire
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease - Yahoo Finance
Alpha Cognition Provides Business Update - Business Wire
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering - Yahoo Finance
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease - Business Wire
BioNTX iC3 Summit to Fuel North Texas Life Science Ecosystem, Honor 8 Rising Stars - dallasinnovates.com
Alpha Cognition gets rating downgrade from Raymond James - Cantech Letter
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire
Data: ALPHA-1062 a Bioequivalent to Approved Therapy Razadyne - Alzheimer's News Today
Progranulin Gene Therapy Shows Promise in Preclinical Studies - ALS News Today
Alpha Cognition could have a best-in-class Alzheimer’s drug, iA Capital says - Cantech Letter
Pharmaceutical Entrepreneur Fred Sancilio Speaks on His Vast Industry Experience - Thrive Global
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Cognition Inc Stock (ACOG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):